Literature DB >> 33418195

Gestational and childhood exposure to per- and polyfluoroalkyl substances and cardiometabolic risk at age 12 years.

Nan Li1, Yun Liu2, George D Papandonatos3, Antonia M Calafat4, Charles B Eaton5, Karl T Kelsey6, Kim M Cecil7, Heidi J Kalkwarf8, Kimberly Yolton9, Bruce P Lanphear10, Aimin Chen11, Joseph M Braun12.   

Abstract

BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) may adversely influence cardiometabolic risk. However, few studies have examined if the timing of early life PFAS exposure modifies their relation to cardiometabolic risk. We examined the influence of gestational and childhood PFAS exposure on adolescents' cardiometabolic risk.
METHODS: We quantified concentrations of four PFAS (perfluorooctanoate [PFOA], perfluorooctane sulfonate [PFOS], perfluorononanoate [PFNA], and perfluorohexane sulfonate [PFHxS]) in sera collected during pregnancy, at birth, and at ages 3, 8, and 12 years from 221 mother-child pairs in the HOME Study (enrolled 2003-06, Cincinnati, Ohio). We measured cardiometabolic risk factors using physical examinations, fasting serum biomarkers, and dual-energy X-ray absorptiometry scans at age 12 years. Cardiometabolic risk summary scores were calculated by summing age- and sex-standardized z-scores for individual cardiometabolic risk factors. We used multiple informant models to estimate covariate-adjusted associations of serum PFAS concentrations (log2-transformed) at each visit with cardiometabolic risk scores and their individual components, and tested for differences in associations across visits.
RESULTS: The associations of serum PFOA concentrations with cardiometabolic risk scores differed across visits (P for heterogeneity = 0.03). Gestational and cord serum PFOA concentrations were positively associated with cardiometabolic risk scores (βs and 95% confidence intervals [95% CIs]: gestational 0.8 [0.0, 1.6]; cord 0.9 [-0.1, 1.9] per interquartile range increase). These positive associations were primarily driven by homeostatic model assessment for insulin resistance index (β = 0.3 [0.1, 0.5]) and adiponectin to leptin ratio (β = -0.5 [-1.0, 0.0]). Other individual cardiometabolic risk factors associated with gestational PFOA included insulin and waist circumference. Gestational and cord PFHxS were also associated with higher cardiometabolic risk scores (βs: gestational 0.9 [0.2, 1.6]; cord 0.9 [0.1, 1.7]).
CONCLUSION: In this cohort of children with higher gestational PFOA exposure, fetal exposure to PFOA and PFHxS was associated with unfavorable cardiometabolic risk in adolescence.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Adolescents; Cardiometabolic risk; PFAS

Mesh:

Substances:

Year:  2021        PMID: 33418195      PMCID: PMC7856172          DOI: 10.1016/j.envint.2020.106344

Source DB:  PubMed          Journal:  Environ Int        ISSN: 0160-4120            Impact factor:   9.621


  140 in total

1.  Age-related patterns of the clustering of cardiovascular risk variables of syndrome X from childhood to young adulthood in a population made up of black and white subjects: the Bogalusa Heart Study.

Authors:  W Chen; W Bao; S Begum; A Elkasabany; S R Srinivasan; G S Berenson
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

2.  Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. 1992.

Authors:  C N Hales; D J P Barker
Journal:  Int J Epidemiol       Date:  2013-10       Impact factor: 7.196

Review 3.  Development of the multiple metabolic syndrome: an epidemiologic perspective.

Authors:  A D Liese; E J Mayer-Davis; S M Haffner
Journal:  Epidemiol Rev       Date:  1998       Impact factor: 6.222

4.  Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project.

Authors:  Stephanie J Frisbee; Anoop Shankar; Sarah S Knox; Kyle Steenland; David A Savitz; Tony Fletcher; Alan M Ducatman
Journal:  Arch Pediatr Adolesc Med       Date:  2010-09

Review 5.  PPARs: therapeutic targets for metabolic disease.

Authors:  Joel P Berger; Taro E Akiyama; Peter T Meinke
Journal:  Trends Pharmacol Sci       Date:  2005-05       Impact factor: 14.819

6.  Effect of pregnancy on the levels of selected perfluoroalkyl compounds for females aged 17-39 years: data from National Health and Nutrition Examination Survey 2003-2008.

Authors:  Ram B Jain
Journal:  J Toxicol Environ Health A       Date:  2013

Review 7.  Continuous cardiometabolic risk score definitions in early childhood: a scoping review.

Authors:  M Kamel; B T Smith; G Wahi; S Carsley; C S Birken; L N Anderson
Journal:  Obes Rev       Date:  2018-09-17       Impact factor: 9.213

Review 8.  Obesogens: an emerging threat to public health.

Authors:  Amanda S Janesick; Bruce Blumberg
Journal:  Am J Obstet Gynecol       Date:  2016-01-29       Impact factor: 8.661

9.  Polyfluoroalkyl compounds in Texas children from birth through 12 years of age.

Authors:  Arnold Schecter; Noor Malik-Bass; Antonia M Calafat; Kayoko Kato; Justin A Colacino; Tyra L Gent; Linda S Hynan; T Robert Harris; Sunitha Malla; Linda Birnbaum
Journal:  Environ Health Perspect       Date:  2011-12-19       Impact factor: 9.031

10.  Perfluoroalkyl substances, metabolomic profiling, and alterations in glucose homeostasis among overweight and obese Hispanic children: A proof-of-concept analysis.

Authors:  Tanya L Alderete; Ran Jin; Douglas I Walker; Damaskini Valvi; Zhanghua Chen; Dean P Jones; Cheng Peng; Frank D Gilliland; Kiros Berhane; David V Conti; Michael I Goran; Lida Chatzi
Journal:  Environ Int       Date:  2019-03-04       Impact factor: 9.621

View more
  6 in total

Review 1.  Non-targeted metabolomics and associations with per- and polyfluoroalkyl substances (PFAS) exposure in humans: A scoping review.

Authors:  Pengfei Guo; Tristan Furnary; Vasilis Vasiliou; Qi Yan; Kate Nyhan; Dean P Jones; Caroline H Johnson; Zeyan Liew
Journal:  Environ Int       Date:  2022-02-26       Impact factor: 9.621

Review 2.  Multiomics to elucidate inflammatory bowel disease risk factors and pathways.

Authors:  Manasi Agrawal; Kristine H Allin; Francesca Petralia; Jean-Frederic Colombel; Tine Jess
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-03-17       Impact factor: 73.082

3.  Latent, sex-specific metabolic health effects in CD-1 mouse offspring exposed to PFOA or HFPO-DA (GenX) during gestation.

Authors:  Harlie A Cope; Bevin E Blake; Charlotte Love; James McCord; Susan A Elmore; Janice B Harvey; Vesna A Chappell; Suzanne E Fenton
Journal:  Emerg Contam       Date:  2021-10-31

4.  Gestational Perfluoroalkyl Substance Exposure and DNA Methylation at Birth and 12 Years of Age: A Longitudinal Epigenome-Wide Association Study.

Authors:  Yun Liu; Melissa N Eliot; George D Papandonatos; Karl T Kelsey; Ruby Fore; Scott Langevin; Jessie Buckley; Aimin Chen; Bruce P Lanphear; Kim M Cecil; Kimberly Yolton; Marie-France Hivert; Sharon K Sagiv; Andrea A Baccarelli; Emily Oken; Joseph M Braun
Journal:  Environ Health Perspect       Date:  2022-03-10       Impact factor: 11.035

5.  Characterization of Potential Adverse Outcome Pathways Related to Metabolic Outcomes and Exposure to Per- and Polyfluoroalkyl Substances Using Artificial Intelligence.

Authors:  Andreas-Marius Kaiser; Maryam Zare Jeddi; Maria Uhl; Florence Jornod; Mariana F Fernandez; Karine Audouze
Journal:  Toxics       Date:  2022-08-04

6.  Associations between exposure to perfluoroalkyl substances and body fat evaluated by DXA and MRI in 109 adolescent boys.

Authors:  Mathilde Lolk Thomsen; Louise Scheutz Henriksen; Jeanette Tinggaard; Flemming Nielsen; Tina Kold Jensen; Katharina M Main
Journal:  Environ Health       Date:  2021-06-28       Impact factor: 5.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.